Tags

Type your tag names separated by a space and hit enter

What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pharmacol Res 2017; 120:279-293PR

Abstract

Multiple Sclerosis (MS) is a chronic pathology affecting the Central Nervous System characterized by inflammatory processes that lead to demyelination and neurodegeneration. In MS treatment, disease modifying therapies (DMTs) are essential to reduce disease progression by suppressing the inflammatory response responsible for promoting lesion formation. Recently, in addition to the classical injectable DMTs like Interferons and Glatiramer acetate, new orally administered drugs have been approved for MS therapy: dimethyl fumarate, teriflunomide and fingolimod. These drugs act with different mechanisms on the immune system, in order to suppress the harmful inflammatory process. An additional layer of complexity is introduced by the influence of polymorphic gene variants in the Human Leukocyte Antigen region on the risk of developing MS and its progression. To date, pharmacogenomic studies have mainly focused on the patient's response following admission of injectable drugs. Therefore, greater consideration must be made to pharmacogenomics with a view to developing more effective and personalized therapies. This review aims to shed light on the mechanism of action of the new oral drugs dimethyl fumarate, teriflunomide and fingolimod, taking into account both the importance of immunogenetics in drug response and pharmacogenomic studies.

Authors+Show Affiliations

Laboratory of Immunogenetics, Department of Biology & Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy. Electronic address: cristiana.pistono01@ateneopv.it.Department of Drug Sciences, Section of Pharmacology, University of Pavia, Pavia, Italy. Electronic address: cecilia.osera@unipv.it.Laboratory of Immunogenetics, Department of Biology & Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.Inter-Department Multiple Sclerosis Research Centre, National Neurological Institute "C. Mondino", Pavia, Italy.Laboratory of Immunogenetics, Department of Biology & Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.Inter-Department Multiple Sclerosis Research Centre, National Neurological Institute "C. Mondino", Pavia, Italy.Department of Drug Sciences, Section of Pharmacology, University of Pavia, Pavia, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28396093

Citation

Pistono, Cristiana, et al. "What's New About Oral Treatments in Multiple Sclerosis? Immunogenetics Still Under Question." Pharmacological Research, vol. 120, 2017, pp. 279-293.
Pistono C, Osera C, Boiocchi C, et al. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. Pharmacol Res. 2017;120:279-293.
Pistono, C., Osera, C., Boiocchi, C., Mallucci, G., Cuccia, M., Bergamaschi, R., & Pascale, A. (2017). What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. Pharmacological Research, 120, pp. 279-293. doi:10.1016/j.phrs.2017.03.025.
Pistono C, et al. What's New About Oral Treatments in Multiple Sclerosis? Immunogenetics Still Under Question. Pharmacol Res. 2017;120:279-293. PubMed PMID: 28396093.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question. AU - Pistono,Cristiana, AU - Osera,Cecilia, AU - Boiocchi,Chiara, AU - Mallucci,Giulia, AU - Cuccia,Mariaclara, AU - Bergamaschi,Roberto, AU - Pascale,Alessia, Y1 - 2017/04/08/ PY - 2017/01/13/received PY - 2017/03/27/revised PY - 2017/03/29/accepted PY - 2017/4/12/pubmed PY - 2018/1/6/medline PY - 2017/4/12/entrez KW - Dimethyl fumarate KW - Dimethyl fumarate (PubChem CID: 637568) KW - Fingolimod KW - Glatiramer acetate (PubChem CID: 3081884) KW - Immunogenetics KW - Multiple sclerosis KW - Teriflunomide KW - fingolimod (PubChem CID: 107970) KW - teriflunomide (PubChem CID: 54684141) SP - 279 EP - 293 JF - Pharmacological research JO - Pharmacol. Res. VL - 120 N2 - Multiple Sclerosis (MS) is a chronic pathology affecting the Central Nervous System characterized by inflammatory processes that lead to demyelination and neurodegeneration. In MS treatment, disease modifying therapies (DMTs) are essential to reduce disease progression by suppressing the inflammatory response responsible for promoting lesion formation. Recently, in addition to the classical injectable DMTs like Interferons and Glatiramer acetate, new orally administered drugs have been approved for MS therapy: dimethyl fumarate, teriflunomide and fingolimod. These drugs act with different mechanisms on the immune system, in order to suppress the harmful inflammatory process. An additional layer of complexity is introduced by the influence of polymorphic gene variants in the Human Leukocyte Antigen region on the risk of developing MS and its progression. To date, pharmacogenomic studies have mainly focused on the patient's response following admission of injectable drugs. Therefore, greater consideration must be made to pharmacogenomics with a view to developing more effective and personalized therapies. This review aims to shed light on the mechanism of action of the new oral drugs dimethyl fumarate, teriflunomide and fingolimod, taking into account both the importance of immunogenetics in drug response and pharmacogenomic studies. SN - 1096-1186 UR - https://www.unboundmedicine.com/medline/citation/28396093/What's_new_about_oral_treatments_in_Multiple_Sclerosis_Immunogenetics_still_under_question_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-6618(17)30037-3 DB - PRIME DP - Unbound Medicine ER -